Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

That’s the message Biogen chief executive Chris Viehbacher ... our weekly Bold Types column about the movers and shakers on Boston’s business scene.

Good morning, Boston. Spring training has begun, and here are the five things you need to know, including Biogen cutbacks, CVS's new CEO, Eastern Nazarene sale, spring training, Rat Day, and more Vale ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

which measured cognitive function using the Apple devices and just generated two-year data that was reported at this week’s DTx in Boston. The study had been billed as a key element in Biogen ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...

Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per ...

(Reuters) -Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.